Treatment outcomes in patients with signet ring cell carcinoma of the colorectum
Treatment outcomes in patients with signet ring cell carcinoma of the colorectum
复制标题
DOI：
10.1016/j.amjsurg.2006.12.041
复制
发表时间：
2007-09-01
影响因子：
3
通讯作者：
Song, Sang Yong
中科院分区：
文献类型：
--
作者：
Lee, Won-Suk;Chun, Ho-Kyung;Song, Sang Yong
背景资料：为探讨印戒细胞癌的临床病理特征及预后，并与结直肠粘液腺癌和低分化腺癌进行比较，方法：回顾分析35例原发印戒细胞癌的临床病理资料，并与294例粘液腺癌和252例低分化腺癌进行比较。80%的SRC患者表现为更晚期的疾病（III期和IV期），而粘液性和低分化组中分别有55.1%和64.7%的患者在诊断时患有晚期疾病（80% vs 55.1%，P = 0.04和80.0% vs 64.7%，P = 0.437）。SRC患者的中位生存时间为18.4个月（95%置信区间为10.4至19.6）。SRC组的3年和5年生存率分别为33.7%和25.3%。SRC患者的总生存率明显低于粘液腺癌和低分化腺癌（P
Background: The aim of this study was to evaluate the clinicopathologic features and prognosis of signet ring cell (SRC) carcinoma and compare them with those of mucinous and poorly differentiated adenocarcinomas of the colorecturn.Methods: The clinicopathologic data of 35 patients with primary SRC carcinoma were reviewed and compared with the data from 294 patients with mucinous and 252 patients with poorly differentiated adenocarcinoma.Results: Eighty percent of the SRC patients presented with more advanced disease (stages III and IV), whereas 55.1% and 64.7% of the patients in the mucinous and poorly differentiated groups had advanced disease at diagnosis, respectively (80% vs 55.1%, P =.04 and 80.0% vs 64.7%, P =.437). Median survival time for patients with SRC was 18.4 months (95% confidence interval 10.4 to 19.6). Three- and 5-year survival rates in the SRC group were 33.7% and 25.3%, respectively. The overall survival rate of patients with SRC was significantly poorer than that of patients with mucinous or poorly differentiated adenocarcinorna (P